Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
ClEAR ALL
Clinical
HIV/AIDS
Product development assistance
7 Results

ACTG Network Laboratory (ACTG NL)

The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.

HIV Drug Development: Analytical Chemistry Services

This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.

HIV Drug Formulation Development and Manufacturing Services

This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.

HIV/TB Drug Development: Chemical Synthesis

This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.

Microbicide Trials Network (MTN) Resources

The Microbicide Trials Network (MTN) is a NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. The MTN accepts concepts for new protocols, ancillary study proposals, secondary data analysis requests, and dataset requests.

NIH AIDS Reagent Program

The National Institutes of Health (NIH) AIDS Reagent Program provides critical research reagents and resources to the scientific community. The ARP acquires, develops, and produces state-of-the-art reagents and provides these reagents at no cost to qualified investigators throughout the world.

Resources to Evaluate New Technologies for Monitoring HIV-infected Patients

Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world.